alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 806.20 Records of corrections and removals not required to be reported. ( a ) Each device manufacturer or importer who initiates a correction or removal of a device that is not required to be reported to FDA under § 806.10 shall keep a record of such correction or removal.
( b ) Records of corrections and removals not required to be reported to FDA under § 806.10 shall contain the following information: ( 1 ) The brand name, common or usual name, classification, name and product code if known, and the intended use of the device.
( 2 ) The unique device identifier (UDI) of the device, or the device identifier, universal product code (UPC), model, catalog, or code number of the device and the manufacturing lot or serial number of the device or other identification number.
( 3 ) A description of the event(s) giving rise to the information reported and the corrective or removal action that has been, and is expected to be taken.
( 4 ) Justification for not reporting the correction or removal action to FDA, which shall contain conclusions and any followups, and be reviewed and evaluated by a designated person.
( 5 ) A copy of all communications regarding the correction or removal.
( c ) The manufacturer or importer shall retain records required under this section for a period of 2 years beyond the expected life of the device, even if the manufacturer or importer has ceased to manufacture or import the device. Records required to be maintained under paragraph (b) of this section must be transferred to the new manufacturer or importer of the device and maintained for the required period of time.
[62 FR 27191, May 19, 1997, as amended at 63 FR 42233, Aug. 7, 1998; 78 FR 58821, Sept. 24, 2013]
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Agriculture

###### Forest Service

# AGENCY:

Forest Service, USDA.

# ACTION:

Notice of meeting.

# SUMMARY:

The Ketchikan Resource Advisory Committee will meet in Ketchikan, Alaska, March 31, 2010. The purpose of this meeting is to discuss potential projects under the Secure Rural Schools and Community Self-Determination Act of 2008.

# DATES:

The meeting will be held March 31, 2010 at 6 pm.

# ADDRESSES:

                        The meeting will be held at the Ketchikan-Misty Fiords Ranger District, 3031 Tongass Avenue, Ketchikan, Alaska. Send written comments to Ketchikan Resource Advisory Committee, do District Ranger, USDA Forest Service, 3031 Tongass Ave., Ketchikan, AK 99901, or electronically to Diane Daniels, RAC Coordinator at                         *ddaniels@fs.fed.us.*

# FOR FURTHER INFORMATION CONTACT:

Diane Daniels, RAC Coordinator Ketchikan-Misty Fiords Ranger District, Tongass National Forest, (907) 228-4105.

# SUPPLEMENTARY INFORMATION:

The meeting is open to the public. Committee discussion is limited to Forest Service staff and Committee members. However, public input opportunity will be provided and individuals will have the opportunity to address the Committee at that time.

Forrest Cole,

Forest Supervisor.

[FR Doc. 2010-3782 Filed 2-25-10; 8:45 am]

BILLING CODE M
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

MERJEME AVILES, as Guardian of PENELOPI BITSI

, Appellant,

v.

HEIDI BITSI,

Appellee

.

No. 4D 22

- 593

[ March 23, 2023 ]

Appeal from the C ircuit Court for the Fifteenth Judicial Circuit, Palm

Beach County ; James Nutt , Judge ; Case No. 502019CA000463

.

Craig A. Boudreau, West Palm Beach, for appellant.

Marshall J. Osofsky, Law Office of Paul A. Krasker, P.A., for appellee.

P ER C URIAM

.

Affirmed

.

G ROSS

, C ONNER and F ORST , JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
<PAGE>

                                                                      EXHIBIT 23

[PHILIP VOGEL & CO. PC LETTERHEAD]


                        Consent of Independent Auditors
                        -------------------------------


The Board of Directors
Preferred Voice, Inc.

We consent to the incorporation by reference in the Registration Statement (Form
S-8 No. 333-56728 and 333-82150) pertaining to Preferred Voice, Inc. 1994 Stock
Plan For Incentive and Non-Qualified Stock Options and 2000 Stock Plan For
Incentive and Non-Qualified Stock Options of our report, dated May 10, 2002,
with respect to the consolidated financial statements of Preferred Voice, Inc.
included in this Annual Report (Form 10-KSB) for the year ended March 31, 2002.



                                                Philip Vogel & Co. PC

                                                /s/ PHILIP VOGEL & Co. PC


Dallas, Texas

June 26, 2002
#### Percy Panarsky, Plaintiff-Appellee, v. Ramon Perez, Defendant-Appellant.

Gen. No. 53,294.

First District, First Division.

April 21, 1969.

Judgment reversed. Ron W. Fritsch, Paul Beard, and Marvin Gerstein, of Chicago, for appellant; no brief for appellee.

Opinion by

JUSTICE MURPHY.

Not to be published in full.
§ 7.53 Recall status reports. ( a ) The recalling firm is requested to submit periodic recall status reports to the appropriate Food and Drug Administration district office so that the agency may assess the progress of the recall. The frequency of such reports will be determined by the relative urgency of the recall and will be specified by the Food and Drug Administration in each recall case; generally the reporting interval will be between 2 and 4 weeks.
( b ) Unless otherwise specified or inappropriate in a given recall case, the recall status report should contain the following information: ( 1 ) Number of consignees notified of the recall, and date and method of notification.
( 2 ) Number of consignees responding to the recall communication and quantity of products on hand at the time it was received.
( 3 ) Number of consignees that did not respond (if needed, the identity of nonresponding consignees may be requested by the Food and Drug Administration).
( 4 ) Number of products returned or corrected by each consignee contacted and the quantity of products accounted for.
( 5 ) Number and results of effectiveness checks that were made.
( 6 ) Estimated time frames for completion of the recall.
( c ) Recall status reports are to be discontinued when the recall is terminated by the Food and Drug Administration.
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 01-50378 Conference Calendar

UNITED STATES OF AMERICA, Plaintiff-Appellee,

versus RAFAEL OLIVARES-AGUIRRE, Defendant-Appellant.

-------------------- Appeal from the United States District Court for the Western District of Texas USDC No. EP-00-CR-1342-ALL-H

-------------------- October 29, 2001 Before WIENER, BENAVIDES, and DENNIS, Circuit Judges.
PER CURIAM: * Rafael Olivares-Aguirre appeals the 37-month term of imprisonment imposed following his guilty plea conviction of attempting to illegally reenter the United States after removal in violation of 8 U.S.C. § 1326. Olivares-Aguirre complains that his sentence was enhanced pursuant to 8 U.S.C. § 1326(b)(2), which allowed the court to impose up to a twenty-year term of imprisonment because he was removed after being convicted of an aggravated felony. Olivares-Aguirre argues that the sentencing provision violates the Due Process Clause because it permittedNo. 01-50378 -2- the sentencing judge to find, under a preponderance of the evidence standard, a fact which increased the statutory maximum sentence to which he otherwise would have been exposed. Olivares-Aguirre thus contends that his sentence is invalid and argues that it should not exceed the two-year maximum term of imprisonment prescribed in 8 U.S.C. § 1326(a). Olivares-Aguirre acknowledges that his argument is foreclosed by the Supreme Court’s decision in Almendarez-Torres v. United States , 523 U.S. 224 (1998), but seeks to preserve the issue for Supreme Court review in light of the decision in Apprendi v. New Jersey , 530 U.S. 466 (2000). Apprendi did not overrule Almendarez-Torres

. See Apprendi , 530 U.S. at 489-90; United States v. Dabeit , 231 F.3d 979, 984 (5th Cir. 2000), cert. denied , 121 S. Ct. 1214 (2001). OlivaresAguirre’s argument is foreclosed. The judgment of the district court is AFFIRMED. The Government has moved for a summary affirmance in lieu of filing an appellee’s brief. In its motion, the Government asks that the judgment of the district court be affirmed and that an appellee’s brief not be required. The motion is GRANTED.
AFFIRMED; MOTION GRANTED.
#### Margaret L. McMahon *v.*Stephen Jankura et al.

*John A. Arcudi,*for the appellant (plaintiff).

*Frank E. Babycos,*for the appellees (defendants).

Argued March 4

decided March 4, 1969

It appearing that the plaintiff in the above-entitled case has failed to prosecute her appeal from the Court of Common Pleas in Fairfield County with proper diligence, it is, under Practice Book § 696, ordered by the Supreme Court, suo motu, that the appeal be and hereby is dismissed.
EXHIBIT 31.2



RULE 13a-14(a)/15d-14(a) CERTIFICATION

I, Richard Dea, Chief Financial Officer, certify that:

1.

I have reviewed this quarterly report on Form 10-QSB of InZon Corporation.

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) [omitted pursuant to extended compliance period] for the small business issuer and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

[omitted pursuant to extended compliance period]

(c)

Evaluated the effectiveness of the small business issuers disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the small business issuers internal control over financial reporting that occurred during the small business issuers most recent fiscal quarter (the small business issuers fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuers internal control over financial reporting; and

5.

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuers auditors and the audit committee of the small business issuers board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuers ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuers internal control over financial reporting.

Dated: May 20, 2008

| |     |                                     
| | --- | ------------------------------------
| | By: | /s/ Richard Dea                     
| |     | Richard Dea, Chief Financial Officer







1
|FORM 6 - K
|----------



|SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549
|--------------------------------------------------------





|Report of Foreign Private
Issuer Pursuant to Rule 13a - 16 or 15d - 16 of 
      the Securities Exchange Act of 1934 As of October 31st, 2002
|---------------------------------------------------------------------------------------------------------------------------------------------

|As of October 31st, 2002
|------------------------



|TUBES OF STEEL OF MEXICO, S.A.(Translation of Registrants name into English)
|-----------------------------------------------------------------------------





|TUBOS DE ACERO DE MEXICO, S.A.Edificio Parque Reforma 
      Campos Eliseos #400 
      Mexico, D.F., 11560 Mexico(Address of principal executive offices)
|----------------------------------------------------------------------------------------------------------------------------------------------------------



|Indicate by check mark whether the registrant
      files or will file annual reports under cover 
      Form 20-F or 40-F.
|---------------------------------------------------------------------------------------------------------------------------



|Form 20-F [X] |  | Form 40-F []
|------------- |  | ------------



|Indicate by check
mark whether the registrant by furnishing the information contained in this Form is also
thereby furnishing the information to the Commission pursuant to Rule 12G3-2(b) under the
Securities Exchange Act of 1934.
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Yes [] |  | No [X]
|------ |  | ------



|If Yes is marked, indicate below the file
      number assigned to the registrant in connection with 
      Rule 12g3-2(b): 82-_____ .
|----------------------------------------------------------------------------------------------------------------------------------------





---





|This report on Form 6-K shall be incorporated by
reference into the registration statement on Form F-4 (File No. 333-99769) of Tenaris S.A.
|-------------------------------------------------------------------------------------------------------------------------------------------



|SIGNATURE
|---------



|Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Date: October 31st, 2002
|------------------------



|Tubos de Acero de México, S.A.
|------------------------------

|By: /s/ Gerardo Varela                        |  | By: /s/ Cecilia Bilesio                  
|--------------------------------------------- |  | -----------------------------------------
|Gerardo Varela 
      Chief Financial Officer |  | Cecilia Bilesio  
      Corporate Affairs

---
§ 830.200 When FDA will act as an issuing agency. ( a ) During any period where there is no accredited issuing agency, FDA will act as an issuing agency.
( b ) If FDA determines that a significant number of small businesses would be substantially and adversely affected by the fees required by all accredited issuing agencies, FDA will act as an issuing agency.
( c ) FDA may, in its discretion, act as an issuing agency if we determine it is necessary for us to do so to ensure the continuity or the effectiveness of the system for the identification of medical devices.
( d ) FDA may, in its discretion, act as an issuing agency if we determine it is appropriate for us to do so in order to facilitate or implement an alternative granted under § 801.55 of this chapter.
IN THE SUPREME COURT OF THE STATE OF MONTANA

IN RE THE MARRIAGE OF ) CASE NO. DA 21-0350

)

DAVINA ATTAR-WILLIAMS, ) 

) ORDER GRANTING MOTION

Petitioner/Appellant, ) TO WITHDRAW

) 

and ) 

)

STEVEN THOMAS WILLIAMS, )

)

Respondent/Appellee. )

____________________________ )

Upon the Motion of Kelly Varnes and Hendrickson Law Firm, P.C., the 

Respondent/Appellee, Steven Thomas Williams having executed a Consent to 

Withdrawal of Counsel, and for good cause shown:

IT IS HEREBY ORDERED that Kelly Varnes and Hendrickson Law Firm, 

P.C., are hereby withdrawn as counsel of record for Respondent/Appellee Steven 

Thomas Williams in the foregoing matter.

DATED this ______ day of ____________________, 2021. 

________________________________

Supreme Court Judge

cc: Kelly Varnes

Davina Attar-Williams

Steven Thomas Williams

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

September 9 2021

09/09/2021

Case Number: DA 21-0350
§ 582.1205 Calcium hydroxide. ( a ) *Product.* Calcium hydroxide.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
§ 520.960 Flumethasone. ( a ) *Specifications.* Each tablet contains 0.0625 milligram of flumethasone.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount* — ( i ) *Dogs:* Administer orally from 0.0625 to 0.25 milligram daily in divided doses.
( ii ) *Cats:* Administer orally from 0.03125 to 0.125 milligram daily in divided doses.
( 2 ) *Indications for use* — ( i ) *Dogs:* It is used for musculoskeletal conditions due to inflammation of muscles or joints and accessory structures, where permanent structural changes do not exist, such as arthritis, the disc syndrome, and myositis.
( ii ) *Dogs and cats:* It is used in certain acute and chronic dermatoses of varying etiology to help control the pruritus, irritation, and inflammation associated with these conditions.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[44 FR 7131, Feb. 6, 1979, as amended at 61 FR 5506, Feb. 13, 1996; 79 FR 28821, May 20, 2014]
<TABLE> <S> <C>


<ARTICLE>                     5
                       
<MULTIPLIER>                  1
<CURRENCY>                    U.S. Dollars                
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>               SEP-30-1998          
<PERIOD-START>                  OCT-01-1997    
<PERIOD-END>                    DEC-31-1997    
<EXCHANGE-RATE>                            1    
<CASH>                               175,432   
<SECURITIES>                               0    
<RECEIVABLES>                          6,300   
<ALLOWANCES>                               0   
<INVENTORY>                                0   
<CURRENT-ASSETS>                     181,732   
<PP&E>                               404,914   
<DEPRECIATION>                       114,453   
<TOTAL-ASSETS>                       472,193   
<CURRENT-LIABILITIES>                 26,796   
<BONDS>                                    0   
<PREFERRED-MANDATORY>                      0   
<PREFERRED>                                0   
<COMMON>                             122,146   
<OTHER-SE>                                 0   
<TOTAL-LIABILITY-AND-EQUITY>         472,193   
<SALES>                                    0   
<TOTAL-REVENUES>                       3,000   
<CGS>                                      0   
<TOTAL-COSTS>                         10,959   
<OTHER-EXPENSES>                           0   
<LOSS-PROVISION>                           0   
<INTEREST-EXPENSE>                      (414)   
<INCOME-PRETAX>                       (7,959)       
<INCOME-TAX>                               0    
<INCOME-CONTINUING>                   (7,959)   
<DISCONTINUED>                             0    
<EXTRAORDINARY>                            0    
<CHANGES>                                  0    
<NET-INCOME>                          (7,959)    
<EPS-PRIMARY>                              0    
<EPS-DILUTED>                              0    
        


</TABLE>
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1307d Ferrous fumarate. ( a ) Ferrous fumarate (iron (II) fumarate, (C4H2FeO4), CAS Reg. No. 141-01-5) is an odorless, reddish-orange to reddish-brown powder. It may contain soft lumps that produce a yellow streak when crushed. It is prepared by admixing hot solutions of ferrous sulfate and sodium fumarate.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), pp. 120-122, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1) the ingredient is used in food as a nutrient supplement as defined in § 170.3(o)(20) of this chapter, with no limitation other than current good manufacturing practice. The ingredient may also be used in infant formula in accordance with section 412(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 350a(g)), or with regulations promulgated under section 412(a)(2) of the act (21 U.S.C. 350a(a)(2)).
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[53 FR 16866, May 12, 1988]